{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:47:51Z","timestamp":1790380071405,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,2,15]]},"abstract":"<jats:p>PURPOSE: Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp). In addition, metabolism of docetaxel by cytochrome P450 (CYP) 3A4 in gut and liver may also contribute. The purpose of this study was to enhance the systemic exposure to oral docetaxel on coadministration of cyclosporine (CsA), an efficacious inhibitor of P-gp and substrate for CYP 3A4.<\/jats:p><jats:p>PATIENTS AND METHODS: A proof-of-concept study was carried out in 14 patients with solid tumors. Patients received one course of oral docetaxel 75 mg\/m<jats:sup>2<\/jats:sup>with or without a single oral dose of CsA 15 mg\/kg. CsA preceded oral docetaxel by 30 minutes. During subsequent courses, patients received intravenous (IV) docetaxel 100 mg\/m<jats:sup>2<\/jats:sup>.<\/jats:p><jats:p>RESULTS: The mean (\u00b1 SD) area under the concentration-time curve (AUC) in patients who received oral docetaxel 75 mg\/m<jats:sup>2<\/jats:sup>without CsA was 0.37 \u00b1 0.33 mg\u00b7h\/L and 2.71 \u00b1 1.81 mg\u00b7h\/L for the same oral docetaxel dose with CsA. The mean AUC of IV docetaxel 100 mg\/m<jats:sup>2<\/jats:sup>was 4.41 \u00b1 2.10 mg\u00b7h\/L. The absolute bioavailability of oral docetaxel was 8% \u00b1 6% without and 90% \u00b1 44% with CsA. The oral combination of docetaxel and CsA was well tolerated.<\/jats:p><jats:p>CONCLUSION: Coadministration of oral CsA strongly enhanced the oral bioavailability of docetaxel. Interpatient variability in the systemic exposure after oral drug administration was of the same order as after IV administration. These data are promising and form the basis for the further development of a clinically useful oral formulation of docetaxel.<\/jats:p>","DOI":"10.1200\/jco.2001.19.4.1160","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:36:16Z","timestamp":1487918176000},"page":"1160-1166","source":"Crossref","is-referenced-by-count":174,"title":["Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel"],"prefix":"10.1200","volume":"19","author":[{"given":"Mirte M.","family":"Malingr\u00e9","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick J.","family":"Richel","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciska J.","family":"Koopman","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim W.","family":"Ten Bokkel Huinink","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Schot","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, the Netherlands Cancer Institute\/Antoni van Leeuwenhoek Hospital, Amsterdam; Department of Pharmacy and Pharmacology, the Netherlands Cancer Institute\/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Utrecht; and Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-085068","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2557"},{"key":"R2-085068","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.110"},{"key":"R3-085068","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.2031"},{"key":"R4-085068","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90580-0"},{"key":"R5-085068","unstructured":"Rowinsky EK, Wright M, Monsarrat B, et al: Clinical pharmacology and metabolism of Taxol (paclitaxel): Update 1993. Ann Oncol 5: S7,1994-S16, (suppl 6)"},{"key":"R6-085068","unstructured":"Marre F, Sanderink G, de Sousa G, et al: Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56: 1296,1996-1302,"},{"key":"R7-085068","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199810000-00004"},{"key":"R8-085068","unstructured":"Van Asperen J, Van Tellingen O, Van der Valk MA, et al: Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4: 2293,1998-2297,"},{"key":"R9-085068","doi-asserted-by":"crossref","unstructured":"Meerum Terwogt JM, Beijnen JH, Ten Bokkel Huinink WW, et al: Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285,1998 (letter)","DOI":"10.1016\/S0140-6736(98)24030-X"},{"key":"R10-085068","unstructured":"Meerum Terwogt JM, Malingr\u00e9 MM, Beijnen JH, et al: Co-administration of cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5: 3379,1999-3384,"},{"key":"R11-085068","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.530"},{"key":"R14-085068","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00209-0"},{"key":"R15-085068","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199202000-00007"},{"key":"R17-085068","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050032"},{"key":"R18-085068","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(93)90059-M"},{"key":"R19-085068","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90137-T"},{"key":"R20-085068","doi-asserted-by":"crossref","unstructured":"Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al: Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24: 655,1996-658,","DOI":"10.1016\/S0090-9556(25)07385-4"},{"key":"R21-085068","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.1997.0068"},{"key":"R22-085068","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90212-7"},{"key":"R23-085068","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2164"},{"key":"R24-085068","unstructured":"L\u00f6ffler TM, Freud W, Dr\u00f6ge C, et al: Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17: 113a,1998 (abstr)"},{"key":"R25-085068","unstructured":"Climent MA, Ruiz A, Llombart-Cussac A, et al: Weekly docetaxel in patients with advanced malignancies: Toxicity profile and activity results. Proc Am Soc Clin Oncol 18: 119a,1999 (abstr 453)"},{"key":"R26-085068","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1269"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.4.1160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T17:17:22Z","timestamp":1750007842000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.4.1160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,15]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,2,15]]}},"alternative-id":["10.1200\/JCO.2001.19.4.1160"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.4.1160","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,15]]}}}